Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Ramping Up For Antegren Launch; Relapsed MS Patients One Target

Executive Summary

Biogen Idec expects to position Antegren to multiple sclerosis patients who are experiencing breakthrough disease upon approval of the monoclonal antibody

You may also be interested in...



Biogen Idec/Elan Tysabri Clears FDA; Promotion Will Focus On Monotherapy

Biogen Idec and Elan plan to promote the once-monthly multiple sclerosis therapy Tysabri primarily as first-line monotherapy to patients who have discontinued previous therapy

Biogen Idec/Elan Tysabri Clears FDA; Promotion Will Focus On Monotherapy

Biogen Idec and Elan plan to promote the once-monthly multiple sclerosis therapy Tysabri primarily as first-line monotherapy to patients who have discontinued previous therapy

Biogen Idec Addressing Avonex Liquid Formulation Manufacturing Problems

Biogen Idec is working to address Avonex fill-finish manufacturing problems with the recently approved liquid formulation of the multiple sclerosis therapy

UsernamePublicRestriction

Register

PS043468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel